The MNOV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNOV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MNOV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MNOV Detailed Price Forecast - CNN Money||View MNOV Detailed Summary - Google Finance|
|View MNOV Detailed Summary - Yahoo! Finance||View MNOV Stock Research & Analysis - Zacks.com|
|View MNOV Trends & Analysis - Trade-Ideas||View MNOV Major Holders - Barrons|
|View MNOV Call Transcripts - NASDAQ||View MNOV Breaking News & Analysis - Seeking Alpha|
|View MNOV Annual Report - CompanySpotlight.com||View MNOV OTC Short Report - OTCShortReport.com|
|View MNOV Fundamentals - TradeKing||View MNOV SEC Filings - Bar Chart|
|View Historical Prices for MNOV - The WSJ||View Performance/Total Return for MNOV - Morningstar|
|View the Analyst Estimates for MNOV - MarketWatch||View the Earnings History for MNOV - CNBC|
|View the MNOV Earnings - StockMarketWatch||View MNOV Buy or Sell Recommendations - MacroAxis|
|View the MNOV Bullish Patterns - American Bulls||View MNOV Short Pain Metrics - ShortPainBot.com|
|View MNOV Stock Mentions - StockTwits||View MNOV Stock Mentions - PennyStockTweets|
|View MNOV Stock Mentions - Twitter||View MNOV Investment Forum News - Investor Hub|
|View MNOV Stock Mentions - Yahoo! Message Board||View MNOV Stock Mentions - Seeking Alpha|
|View Insider Transactions for MNOV - SECform4.com||View Insider Transactions for MNOV - Insider Cow|
|View MNOV Major Holdings Summary - CNBC||View Insider Disclosure for MNOV - OTC Markets|
|View Insider Transactions for MNOV - Yahoo! Finance||View Institutional Holdings for MNOV - NASDAQ|
|View MNOV Stock Insight & Charts - FinViz.com||View MNOV Investment Charts - StockCharts.com|
|View MNOV Stock Overview & Charts - BarChart||View MNOV User Generated Charts - Trading View|
The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
Posted on Friday October 05, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...
MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
Posted on Thursday October 04, 2018
LA JOLLA, Calif., Oct. 04, 2018 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.
MNOV: Positive FDA Feedback on ALS Phase 3 Plan…
Posted on Friday September 28, 2018
On September 25, 2018, MediciNova, Inc. (MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The FDA did not raise any concerns with the safety of MN-166, only a single trial may be necessary if there is a statistically significant result when comparing MN-166 to placebo in a functional outcome (such as ALSFRS-R), and the agency would like to see a broad range of ALS patients with randomization stratified by baseline disease severity.
MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
Posted on Tuesday September 25, 2018
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FDA (U.S. Food and Drug Administration) regarding MediciNova’s Phase 3 clinical development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If a single trial shows that MN-166 (ibudilast) has a statistically significant benefit compared to placebo in a measure of functional activity, such as ALSFRS-R, an additional trial may not be necessary. In order to detect the maximal potential benefit of MN-166 (ibudilast), FDA encouraged including a broad ALS population, with randomization that is stratified by baseline disease severity.